1. Introduction {#s0005}
===============

As the global rate of obesity has more than doubled in recent decades, the rates of associated metabolic disorders, including diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, have also increased markedly. Low-grade sustained inflammation links obesity to insulin resistance and its comorbidities, such as type 2 diabetes and NAFLD ([@bb0075], [@bb0190]). Excessive fat accumulation increases the infiltration of proinflammatory immune cells into metabolic tissues and causes phenotypic shifts in macrophages, leading to the development of insulin resistance ([@bb0105], [@bb0215]). However, therapeutic approaches for improving systemic energy balance and chronic inflammation in obesity are limited.

Sodium glucose cotransporter-2 (SGLT2) inhibitors have emerged as a promising new class of glucose-lowering drugs for the management of type 2 diabetes. SGLT2 inhibitors increase urinary glucose excretion (UGE), thereby reducing hyperglycaemia and weight with apparent pleiotropic effects ([@bb0030], [@bb0090]). When large amounts of glucose are forced into urinary excretion processes, whole-body metabolism undergoes adaptive changes involving glucose fluxes, hormonal responses, and fuel selection ([@bb0185]). Recent clinical studies have shown that the treatment of type 2 diabetes with SGLT2 inhibitors paradoxically increases endogenous glucose production (EGP) despite an overall reduction in fasting hyperglycaemia ([@bb0035], [@bb0115]). Moreover, the chronic administration of empagliflozin drives a fuel shift in which tissue glucose disposal decreases, and lipid use increases ([@bb0040], [@bb0035]), although the mechanisms underlying these effects have yet to be determined.

These observations indicate a unique mode of action of SGLT2 inhibitors in which they operate independently of the insulin pathway and yield favourable effects on obesity, ectopic fat accumulation and comorbidities such as insulin resistance and NAFLD. However, the effects of SGLT2 inhibition on energy homeostasis and obesity-associated inflammation remain largely unknown. Therefore, this study aimed to examine the effects of the SGLT2 inhibitor empagliflozin on systemic energy balance and chronic inflammation in high-fat-diet (HFD)-induced obese (DIO) mice.

2. Materials and Methods {#s0010}
========================

2.1. Animals and Diets {#s0015}
----------------------

Eight-week-old male C57BL/6J mice (Hamamatsu, Japan) were randomly divided into four groups and pair-fed for 16 weeks as follows: (1) normal chow (NC) with 10% of calories from fat (CRF-1, Charles River Laboratories, Wilmington, MA); (2) HFD with 60% of calories from fat (D12492, Research Diets, New Brunswick, NJ); (3) HFD with 0.003% (w/w) empagliflozin (Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; HFD + Lo Empa, equivalent to 3 mg/kg bodyweight); or (4) HFD with 0.01% (w/w) empagliflozin (HFD + Hi Empa, equivalent to 10 mg/kg bodyweight). All animal procedures were performed in accordance with the standards set forth in the Guidelines for the Care and Use of Laboratory Animals at Kanazawa University, Japan.

2.2. Indirect Calorimetry {#s0020}
-------------------------

After 6 weeks of feeding, the mice were housed individually in indirect calorimeter chambers (Oxymax; Columbus Instruments, Columbus, OH). Calorimetry, daily body weights, and daily food intake data were measured during a 3-day acclimation period followed by a 2-day experimental period. Oxygen consumption (VO~2~), carbon dioxide production (*V*CO~2~), and respiratory exchange ratio (RER, VCO~2~/VO~2~) were evaluated for 2 consecutive days. Energy expenditure was calculated by the formula as energy expenditure = VO~2~ × \[3.815 + (1.232 × RER)\] and normalized to the body mass of each subject. Rectal temperature was measured on 3 consecutive days between 9 and 10 am using a microprobe thermometer (Physitemp Instruments, Clifton, NJ).

2.3. Fluorescence-activated Cell Sorting (FACS) {#s0025}
-----------------------------------------------

Cells from the liver and epididymal white adipose tissue (eWAT) were prepared as previously described ([@bb0100], [@bb0135]). The isolated cells were incubated with Fc-Block (BD Bioscience, San Jose, CA), followed by incubation with fluorochrome-conjugated antibodies (Supplementary Table 1). Flow cytometry was performed using a FACSAria II (BD Bioscience), and the data were analysed using the FlowJo software (Tree Star, Ashland, OR).

2.4. Immunohistochemistry {#s0030}
-------------------------

Paraffin-embedded eWAT, liver, and brown adipose tissue (BAT) sections were immunohistochemically stained for F4/80 and uncoupling protein (UCP) 1 as previously described ([@bb0015], [@bb0230]). The quantification of the positive area were calculated by ImageJ software (Version 1.50). The pancreas was stained with anti-insulin and anti-glucagon antibodies (Abcam, Cambridge, UK) followed by secondary antibodies (AlexaFluor 594, AlexaFluor 488; Jackson ImmunoResearch Laboratories, Baltimore, MD) using standard techniques.

2.5. Computed Tomography (CT) {#s0035}
-----------------------------

Abdominal fat mass were determined by computed tomography (CT). Briefly, 21-week-old mice (*n* = 6) of each group were scanned by using Latheta LCT-200 (Hitachi-Aloka, Tokyo, Japan) while animals were under 2% isoflurane anaesthesia. Adipose tissue mass in the abdominal region between the proximal end of lumbar vertebra L1 and the distal end of L6 was scanned. And the visceral and subcutaneous fat depots of the area was analysed.

2.6. Biochemical Analyses {#s0040}
-------------------------

Plasma triglycerides (TG), total cholesterol (TC), non-esterified fatty acid (NEFA), glucose, insulin, glucagon, aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-α (TNFα), fibroblast growth factor 21 (FGF21), ketone body, glycerol, creatinine and hepatic lipids, ketone body, thiobarbituric acid-reactive substrates (TBARS) concentrations, and urine 8-hydroxy-2′-deoxyguanosine (8-OHdG) contents were measured as described previously ([@bb0140], [@bb0160]).

2.7. GTTs and ITTs {#s0045}
------------------

The glucose tolerance test (GTT) was conducted after an overnight fast, and the mice were then injected with 2 g/kg glucose i.p. The insulin tolerance test (ITT) was performed after a 4-h fast, and mice were injected with 1 U/kg human insulin i.p.

2.8. Urinary Glucose Extraction {#s0050}
-------------------------------

Mice were housed individually in metabolic cages for 24 h and urine samples were collected and urine volume was measured. Urinary glucose concentration was determined by glucose C2 test kit (Wako Life Sciences, Inc. Osaka, Japan).

2.9. Detection of mRNAs and Proteins {#s0055}
------------------------------------

Relative quantification real-time polymerase chain reaction (PCR) and Western blot analyses were performed as described previously ([@bb0100]). Primers used for real-time PCR are shown in Supplementary Table 2, and primary antibodies for Western blotting are shown in Supplementary Table 3.

2.10. Statistics {#s0060}
----------------

Results are reported as the means ± SEM. Differences between the mean values were assessed using a two-tailed Student\'s *t*-test or ANOVA. *P* values \< 0.05 were considered significant.

3. Results {#s0065}
==========

3.1. Empagliflozin Reduces Weight and Adiposity and Increases UGE in DIO Mice {#s0070}
-----------------------------------------------------------------------------

C57BL/6J mice were pair-fed the NC, HFD, or HFD containing empagliflozin for 16 weeks. The high-dose of empagliflozin suppressed weight gain ([Fig. 1](#f0005){ref-type="fig"}a) independently of food intake ([Fig. 1](#f0005){ref-type="fig"}b, Supplementary Table 4). However, empagliflozin dose-dependently increased water intake ([Fig. 1](#f0005){ref-type="fig"}c). The results from the CT scans showed that abdominal fat accumulation was dose-dependently decreased by empagliflozin in the DIO mice ([Fig. 1](#f0005){ref-type="fig"}d, e), and the weights of the visceral and subcutaneous fat depots were consistently decreased by administration of empagliflozin ([Fig. 1](#f0005){ref-type="fig"}f). Additionally, the liver and BAT weights were lower in the HFD + Hi Empa group than in the HFD group, whereas the kidney weights increased with both doses of empagliflozin ([Fig. 1](#f0005){ref-type="fig"}g). The femoral muscle weight was unaffected by empagliflozin (Supplementary Fig. [1](#f0005){ref-type="fig"}a, b). Moreover, administration of empagliflozin dose-dependently increased urine volume and UGE ([Fig. 1](#f0005){ref-type="fig"}h). The genes *Slc5a1* and *Slc5a2*, encoding SGLT1 and SGLT2, respectively, were dose-dependently upregulated in the kidney by empagliflozin (Supplementary Fig. 1c). However, plasma creatinine levels, which are an indicator of renal function, were unaffected by empagliflozin (Supplementary Fig. 1d). Taken together, these data indicate that the weight reduction by empagliflozin was largely attributable to decreases in both visceral and subcutaneous fat depots under pair-fed conditions and that there was no effect on renal function.Fig. 1Empagliflozin reduces weight gain in DIO mice. (a) Body weights. (b, c) Food and water intake. (d) Representative CT images. (e) Fat mass calculated from CT scans. (f, g) Fat depot and tissue weights. (h) Urine volume and urinary glucose. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 1

3.2. Empagliflozin Ameliorates HFD-induced Insulin Resistance {#s0075}
-------------------------------------------------------------

The high-dose of empagliflozin normalized postprandial hyperglycaemia in the DIO mice ([Fig. 2](#f0010){ref-type="fig"}a). The GTT and ITT data showed that glucose intolerance and insulin resistance were ameliorated by empagliflozin ([Fig. 2](#f0010){ref-type="fig"}b, c), and hyperinsulinemia in fed and fasting states were suppressed ([Fig. 2](#f0010){ref-type="fig"}d). Moreover, the expression levels of *G6pc* and *Pepck*, which are involved in EGP, were elevated by empagliflozin in the DIO mice (Supplementary Fig. 2a). Consistent with these findings, empagliflozin increased fasting glucagon levels (Supplementary Fig. 2b), resulting in a reduced ratio of insulin to glucagon ([Fig. 2](#f0010){ref-type="fig"}e). The immunofluorescence analysis revealed that the number and size of the pancreatic islets were increased in the DIO mice, whereas they were dose-dependently decreased by empagliflozin ([Fig. 2](#f0010){ref-type="fig"}f, g). Finally, we found the insulin-stimulated phosphorylation of the insulin receptor β subunit (Tyr1146) and Akt (Ser473) in eWAT, liver, and muscle was increased in the HFD + Empa mice compared to the HFD mice (Supplementary Fig. 2c).Fig. 2Empagliflozin ameliorates diet-induced insulin resistance. (a) Fed blood glucose levels. (b, c) GTT and ITT. (d) Plasma insulin levels. (e) Ratio of plasma insulin to glucagon levels. (f) Representative insulin and glucagon-stained pancreas sections. Scale bars = 100 μm. (g) Islet numbers and sizes. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 2

3.3. Empagliflozin Increases Energy Expenditure {#s0080}
-----------------------------------------------

To assess whole-body energy expenditure, we placed the mice in open-circuit indirect calorimetry cages after 6 weeks of feeding, before an evident change in the body mass of HFD-fed mice was observed. The HFD did not alter *V*O~2~, but it significantly suppressed *V*CO~2~, RER, and energy expenditure ([Fig. 3](#f0015){ref-type="fig"}a--d). Empagliflozin-treated mice that were fed the HFD exhibited consistently higher oxygen consumption and tended to exhale more CO~2~ than the HFD-fed controls, leading to elevated energy expenditure ([Fig. 3](#f0015){ref-type="fig"}a, b, d) although they displayed similar RERs ([Fig. 3](#f0015){ref-type="fig"}c). These data suggest that empagliflozin treatment enhances the utilization of both sugar and fat under HFD conditions. Consistent with this increase in energy expenditure, empagliflozin also increased the core temperature of the mice fed the HFD by \~ 1 °C ([Fig. 3](#f0015){ref-type="fig"}e). These results indicate that empagliflozin reduces obesity by increasing energy expenditure.Fig. 3Empagliflozin increases energy expenditure in DIO mice. (a) Oxygen consumption (*V*O~2~). (b) Carbon dioxide production (*V*CO~2~). (c) Respiratory exchange ratio (RER). (d) Energy expenditure. (e) Rectal temperature. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 3

3.4. Empagliflozin Promotes the Browning of Fat in DIO Mice {#s0085}
-----------------------------------------------------------

The increased energy expenditure and body temperature of the empagliflozin-treated, HFD-fed mice suggested an increase in adaptive thermogenesis. Indeed, empagliflozin decreased lipid accumulation ([Fig. 4](#f0020){ref-type="fig"}a), and increased the number of UCP1^+^ cells in the interscapular BAT ([Fig. 4](#f0020){ref-type="fig"}b, Supplementary Fig. 3a). The mRNA levels of brown fat-selective genes were also significantly upregulated by empagliflozin ([Fig. 4](#f0020){ref-type="fig"}c). Furthermore, empagliflozin increased UCP1 protein levels in BAT ([Fig. 4](#f0020){ref-type="fig"}d). Brown-like adipocytes expressing UCP1, also known as beige cells, exist in various WAT depots and can contribute to thermogenesis ([@bb0020]). The HFD significantly decreased UCP1 protein levels in both eWAT and inguinal WAT (iWAT) compared with NC, and these levels were restored by empagliflozin ([Fig. 4](#f0020){ref-type="fig"}d). Consistent with the immunoblotting data, empagliflozin also increased the number of UCP1^+^ cells in both eWAT and iWAT (Supplementary Fig. 3b, c). Additionally, the mRNA levels of beige-selective genes were increased in iWAT (Supplementary Fig. 3d). Thus, empagliflozin appears to promote fat browning, thereby enhancing energy expenditure in these obese mice.Fig. 4Empagliflozin increases UCP1 levels in BAT and beige fat. (a) H&E-stained BAT sections. Scale bars = 100 μm. (b) UCP1-stained BAT sections. Scale bars = 100 μm. (c) mRNA expression of brown fat-related genes. (d) Immunobloting and quantitation of UCP1 in BAT, eWAT and iWAT. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 4

3.5. Empagliflozin Activates AMP-activated Protein Kinase and Enhances Fatty Acid Oxidation in Skeletal Muscle {#s0090}
--------------------------------------------------------------------------------------------------------------

Empagliflozin suppressed HFD-induced TG accumulation, associated with the upregulated mRNA expression of fatty acid β-oxidation genes in skeletal muscle ([Fig. 5](#f0025){ref-type="fig"}a, b). Furthermore, empagliflozin increased the urinary excretion of ketone bodies and their plasma levels ([Fig. 5](#f0025){ref-type="fig"}c). The phosphorylation of AMP-activated protein kinase (AMPKα; at Thr^172^) and acetyl-CoA carboxylase (ACC; at Ser^79^) was increased by empagliflozin ([Fig. 5](#f0025){ref-type="fig"}d), suggesting that empagliflozin activates AMPK and enhances fat oxidation in skeletal muscle.Fig. 5Empagliflozin enhances fat utilization in skeletal muscle. (a) Muscle TG content. (b) mRNA expression of fatty acid oxidation-related genes. (c) Urinary ketone body and fasting plasma ketone body concentrations. (d) Immunoblotting of skeletal muscle lysates. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 5

3.6. Empagliflozin Attenuates Obesity-induced Inflammation in WAT {#s0095}
-----------------------------------------------------------------

We next evaluated the effects of empagliflozin on adipose tissue biology. The mean adipocyte size in eWAT was increased 2.5-fold in the HFD group, and this increase was significantly suppressed by empagliflozin ([Fig. 6](#f0030){ref-type="fig"}a, b). The mRNA levels of fatty acid synthesis-related genes were consistently decreased by empagliflozin ([Fig. 6](#f0030){ref-type="fig"}d). In contrast, the mRNA levels for of fatty acid β-oxidation-related genes were increased by empagliflozin ([Fig. 6](#f0030){ref-type="fig"}d). The obesity-associated aberrant expression of adipokines, such as *leptin* and *adiponectin*, was also improved by empagliflozin ([Fig. 6](#f0030){ref-type="fig"}e).Fig. 6Empagliflozin attenuates adipose tissue inflammation. (a) F4/80 immunostaining in eWAT. Scale bars = 100 μm. (b) Adipocyte sizes. (c) The F4/80^+^-cell ratio. (d) mRNA expression of lipometabolic-related genes. (e) mRNA expression of adipocytokine genes. (f) mRNA expression of F4/80 and inflammatory cytokines and chemokines. (g) Plasma levels of TNFα. (h) mRNA expression of M2 marker genes. (i) Immunoblotting of eWAT lysates. (j) Urinary 8-OHdG levels and TBARS content in eWAT and plasma. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 6

According to the immunostaining and mRNA expression of F4/80, empagliflozin markedly decreased the infiltration of macrophages into the hypertrophic adipose tissue and crown-like structures ([Fig. 6](#f0030){ref-type="fig"}a, c, and f), and iWAT (Supplementary Fig. 4a) of the DIO mice. The levels of inflammatory chemokines and cytokines derived from M1 macrophages were decreased in the eWAT of the HFD + Empa mice ([Fig. 6](#f0030){ref-type="fig"}f). The plasma levels of TNFα were markedly lower in the HFD + Empa mice than in the HFD mice ([Fig. 6](#f0030){ref-type="fig"}g). In contrast, empagliflozin upregulated the mRNA levels of the anti-inflammatory and M2 macrophage markers ([Fig. 6](#f0030){ref-type="fig"}h). Empagliflozin also attenuated the phosphorylation of JNK and ERK1/2, although the phosphorylation levels of p38 MAPK and NF-κB p65 were comparable among the treatment groups ([Fig. 6](#f0030){ref-type="fig"}i, Supplementary Fig. 4b). Furthermore, the increase in endoplasmic reticulum stress in the DIO mice, as assessed by GRP78 and CHOP protein levels, as well as *spliced XBP1(sXBP1)* and *Grp78* mRNA expression, was suppressed by empagliflozin ([Fig. 6](#f0030){ref-type="fig"}i, Supplementary Fig. 4b, c).

The levels of urinary 8-OHdG, a marker of oxidized DNA damage, were increased, but empagliflozin decreased the levels markedly ([Fig. 6](#f0030){ref-type="fig"}j). Empagliflozin also suppressed the levels of TBARS, an indicator of lipid peroxidation, in eWAT and plasma by 35.3% and 28.7%, respectively ([Fig. 6](#f0030){ref-type="fig"}j). These findings were observed in association with decreased mRNA expression of the subunits of NADPH oxidase (Supplementary Fig. 4d) and increased mRNA expression of anti-oxidative stress genes in the eWAT of the DIO mice (Supplementary Fig. 4e).

3.7. Empagliflozin Protects Mice from Diet-induced Hepatic Steatosis and Inflammation {#s0100}
-------------------------------------------------------------------------------------

The histological analysis revealed severe lipid accumulation in the livers of the mice fed the HFD, which was decreased markedly by empagliflozin ([Fig. 7](#f0035){ref-type="fig"}a). Empagliflozin consistently reduced the liver TG, TC, and NEFA levels in the HFD-fed mice ([Fig. 7](#f0035){ref-type="fig"}b), and these findings were associated with the suppression of lipogenic gene expression and the upregulation of mitochondrial fatty acid β-oxidation genes ([Fig. 7](#f0035){ref-type="fig"}c). Moreover, the changes in plasma glycerol levels induced by lipolysis were increased by empagliflozin (Supplementary Table 4). The administration of empagliflozin caused an elevation in the levels of hepatic ketone bodies (Supplementary Fig. 5a) but decreased the levels of plasma AST and ALT; plasma lipid levels were not significantly affected (Supplementary Table 4).Fig. 7Empagliflozin ameliorates hepatic steatosis and inflammation. (a) H&E-stained liver sections. Scale bars = 100 μm. (b) Hepatic lipid content. (c) mRNA levels of lipogenic regulator genes. (d) F4/80 immunostaining. Scale bars = 100 μm. (e) mRNA expression of F4/80 and inflammatory cytokines and chemokines. (f) mRNA expression of M2 marker genes. (g) Immunoblotting of liver lysates. (h) TBARS content. (i) mRNA expression of FGF21 in the liver and plasma levels of FGF21. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 7

As with WAT, empagliflozin also markedly decreased the number of F4/80^+^ cells ([Fig. 7](#f0035){ref-type="fig"}d, e, Supplementary Fig. 5b) and the mRNA expression of proinflammatory cytokines and chemokines in the liver ([Fig. 7](#f0035){ref-type="fig"}e), whereas it increased the mRNA levels of anti-inflammatory and M2 macrophage markers ([Fig. 7](#f0035){ref-type="fig"}f). These changes were associated with attenuated phosphorylation of NF-κB p65 and JNK and reduced CHOP expression in the liver ([Fig. 7](#f0035){ref-type="fig"}g, Supplementary Fig. 5c). Furthermore, the TBARS levels and gene expression of the NADPH oxidase subunits were decreased in the HFD + Empa group compared with the HFD group ([Fig. 7](#f0035){ref-type="fig"}h, Supplementary Fig. 5d). However, empagliflozin increased the mRNA levels of anti-oxidative stress genes (Supplementary Fig. 5e). Furthermore, the hepatic mRNA levels of fibroblast growth factor (FGF21) and the plasma levels of FGF21 were increased by empagliflozin in the DIO mice ([Fig. 7](#f0035){ref-type="fig"}i). These data suggest that FGF21 can mediate a shift of energy metabolism towards fat utilization in response to SGLT2 inhibition.

3.8. Reciprocal Decreases in M1 Macrophages and Increases in M2 Macrophages in Empagliflozin-fed Mice {#s0105}
-----------------------------------------------------------------------------------------------------

To further quantify the adipose tissue macrophages (ATMs) and hepatic macrophage/Kupffer cell subsets, FACS was used to analyse the immune cells isolated from the mice. The increase in the total number of ATMs associated with HFD feeding was decreased slightly by empagliflozin ([Fig. 8](#f0040){ref-type="fig"}a, c), and the HFD-fed mice exhibited significantly higher M1 and lower M2 expression levels within the ATMs. The high-dose of empagliflozin caused a 49% decrease in M1 ATMs and a 3.3-fold increase in M2 ATMs compared with HFD feeding, resulting in macrophage polarization towards an anti-inflammatory phenotype ([Fig. 8](#f0040){ref-type="fig"}b, c).Fig. 8Empagliflozin treatment leads to a predominance of M2 macrophage populations over M1 in the WAT and liver. (a) Representative plots of total ATMs in eWAT. (b) M1 and M2 macrophages in eWAT. (c) Quantitation of total counts of ATMs, M1 ATMs, and M2 ATMs and M1/M2 ratios. (d) Representative plots of total LMs. (e) M1 and M2 macrophages in the liver. (f) Quantitation of total counts of LMs, M1 LMs, and M2 LMs and M1/M2 ratios. Data are presented as means ± SEM, *n* = 7--9. \**P* \< 0.05, \*\**P* \< 0.01 vs. NC; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. HFD.Fig. 8

Moreover, the total number of liver macrophages (LMs) was increased in the mice fed the HFD compared with the NC diet ([Fig. 8](#f0040){ref-type="fig"}d, f). In addition to the reduction in total LM content, the empagliflozin-treated mice had fewer M1 LMs and more M2 LMs than the HFD-fed mice, resulting in macrophage polarization towards an anti-inflammatory phenotype in the liver ([Fig. 8](#f0040){ref-type="fig"}e, f). Moreover, the total number of CD3^+^, CD4^+^, and CD8^+^ T cells in the eWAT and liver increased with HFD feeding, but this effect was significantly decreased by empagliflozin (Supplementary Fig. 6a--d). These results suggest that empagliflozin causes a shift to an M2-dominant macrophage phenotype and reduces T cell accumulation in the liver and WAT, contributing to the attenuation of obesity-induced insulin resistance and inflammation.

4. Discussion {#s0110}
=============

The present study provides evidence that SGLT2 inhibition is associated with the substantial impacts of empagliflozin on energy homeostasis, obesity-induced inflammation, and insulin resistance. Several studies have demonstrated the protective effects of SGLT2 inhibitors against obesity in rodents. In 8-week-old pair-fed animals, tofogliflozin suppressed HFD-induced weight gain and hepatic steatosis ([@bb0150]). In contrast, 4 weeks of treatment with remogliflozin following 11 weeks of HFD feeding attenuated hepatic steatosis without affecting weight gain ([@bb0120]). Another report showed that luseogliflozin decreased liver weight and ameliorated steatohepatitis in streptozotocin-treated mice that were fed a HFD, and it did so without altering weight gain ([@bb0170]). However, the effects of SGLT2 inhibition on energy homeostasis and obesity-related inflammation remain largely unknown. Because SGLT2 inhibitors have been shown to augment food intake in rodents ([@bb0025], [@bb0150]), we pair-fed the mice to clarify the effect of SGLT2 inhibition on obesity and its comorbidities. Notably, empagliflozin reduced adiposity via increased energy expenditure and caloric loss due to glucosuria. Notable weight loss, particularly in HFD + Hi Empa group, could contribute to the amelioration of obesity-related insulin resistance and metabolic phenotype. The relative expression levels of *Slc5a1* and *Slc5a2* in the kidney were increased, possibly due to a compensatory response to SGLT2 inhibition, as previously reported ([@bb0180]).

Although the present study revealed that increased UGE drove reductions in adiposity and ectopic fat, these findings may be limited because the effects of empagliflozin were evaluated using preventative treatments rather than a therapeutic study design. Additional therapeutic studies will aid in the translation of experimental results regarding the anti-obesity effects of SGLT2 inhibitors to clinical settings. The differences among the clinical doses of empagliflozin used for humans (10 and 25 mg/d) and the experimental doses used for rats (3 mg/kg/d) ([@bb0200]) and mice (3 and 10 mg/kg/d) in the present study may reflect differences in the pharmacokinetic parameters between humans and rodents. The linear pharmacokinetics of empagliflozin indicate that the maximum plasma concentration (C~max~) after 3 mg/kg of this drug is administered can be estimated as approximately 500 nM; even if a 10-fold higher concentration is assumed to be present in the kidney, this would still be below the apparent Ki (inhibition constant; 8500 nM) of empagliflozin for SGLT-1 ([@bb0055]). Therefore, the relevant inhibition of human, mouse, or rat SGLT-1 by pharmacological doses of empagliflozin would not be expected.

Pharmacologically induced glucosuria leads to adaptive responses in glucose homeostasis and hormone release, and the genetic or pharmacological inhibition of SGLT2 has beneficial effects on hyperinsulinemia and hyperglycaemia ([@bb0195], [@bb0205]). Conversely, SGLT2 inhibition induces EGP in mice ([@bb0010], [@bb0125]). In patients with type 2 diabetes, SGLT2 inhibitors also increase EGP and plasma glucagon levels, as well as decrease plasma glucose and insulin levels ([@bb0035], [@bb0115]). The empagliflozin-induced hormonal change in relative hyperglucagonemia can be explained by reductions in glycaemia and insulin release, as insulin normally restrains glucagon secretion via paracrine action ([@bb0110]). Moreover, a recent study suggested that the inhibition of SGLT2 with dapagliflozin directly triggered glucagon secretion in pancreatic alpha-cells ([@bb0010]). Our study confirmed that empagliflozin induced the expression of genes involved in hepatic glucose production and glucagon release and reduced the ratio of insulin to glucagon. Moreover, empagliflozin decreased the number and size of pancreatic islets, although it did not alter alpha-cell mass. These results suggest that the suppression of hyperinsulinemia by empagliflozin causes relative hyperglucagonemia and increases EGP. This relative hyperglucagonemia may promote lipolysis, contributing to fat utilization and the release of ketone bodies in DIO mice.

Consistent with previous reports demonstrating the anti-obesity effects of SGLT2 inhibitors ([@bb0025], [@bb0120], [@bb0225]), we found that the administration of empagliflozin mitigated HFD-induced weight gain and fatty liver changes. Our findings suggest an underlying mechanism for the weight reduction that depends partially on increased energy expenditure and enhanced fatty acid oxidation. In our study, empagliflozin enhances the phosphorylation of AMPKα and ACC in skeletal muscle. A recent study found that canagliflozin activates AMPK in vitro and lowers liver lipid content ([@bb0070]). Once activated, AMPK acts to restore energy homeostasis by promoting catabolic pathways, including fatty acid oxidation, while inhibiting anabolic pathways, including fatty acid synthesis ([@bb0060], [@bb0065]). Adiponectin activates AMPK via adiponectin receptor 1 in skeletal muscle ([@bb0220]). Moreover, the inhibition of SGLT2 increases energy expenditure, leading to the increase of AMP/ATP ([@bb0050]). Therefore, the potential mechanisms of activation of AMPK by empagliflozin are, at least in part, via increased adiponectin expression in WAT and elevation of AMP/ATP. Because the phosphorylation of ACC by AMPK is known to lower muscle lipid content, our results suggest a potential benefit of empagliflozin and other SGLT2 inhibitors in protecting against obesity or ectopic fat accumulation. In the present study, the low dose of empagliflozin tended to increase the phosphorylation levels of ACC and AMPK, which contributed to the decreases in ectopic fat in the liver and muscle in the absence of weight reduction.

An important finding of this study is that empagliflozin increases whole-body energy expenditure, and the protein levels of UCP1 in both BAT and WAT. These data suggest that empagliflozin promotes adipose tissue browning. Recent studies have demonstrated that M2-polarized macrophages play a key role in the browning of WAT via the activation of type 2 cytokine production during cold exposure ([@bb0130], [@bb0175]). In response to cold exposure, various cytokines are released from M2-type macrophages; these include catecholamines, which activate β-adrenergic receptors in adipocytes to turn on the thermogenic program, including the induction of UCP1. Moreover, adiponectin plays a role in promoting beige adipocytes ([@bb0080]). We found that empagliflozin causes M2 polarization in macrophages and increases adiponectin levels in WAT, which can lead to adipose tissue browning.

FGF21 has emerged as a key mediator of metabolic processes and contributes to the regulation of lipolysis in WAT ([@bb0085]), and the increase in fatty acid oxidation in the liver ([@bb0005]). FGF21 also activates the β~3~-adrenergic receptor in WAT and regulates the recruitment of beige adipocytes ([@bb0045]). The systemic administration of FGF21 leads to weight loss in obese mouse models through increases in energy expenditure ([@bb0095]). Thus, increased FGF21 in the liver and circulation following empagliflozin administration may be another factor promoting fat utilization and browning under the conditions of obesity.

Obesity or ectopic fat accumulation induces an innate immune response with the subsequent recruitment of immune cells, which ultimately leads to the development of insulin resistance and non-alcoholic steatohepatitis (NASH). In particular, macrophage recruitment and polarization are pivotal to obesity-induced inflammation and insulin resistance ([@bb0105], [@bb0215]). Thus, strategies to restrain M1 polarization and/or drive the alternative M2 activation of macrophages may have the potential to protect against exacerbated inflammation and insulin resistance and may even attenuate the progression to NASH ([@bb0155], [@bb0165], [@bb0210]). Our results indicate that empagliflozin attenuates obesity-related inflammation by decreasing macrophage accumulation and causing an M2-dominant phenotypic shift of macrophages in the WAT and liver. Additionally, the infiltration of Th1 and CD8^+^ T cells precedes M1-polarized macrophage recruitment, and the interactions between the T cells and macrophages constitute a maladaptive feed-forward loop that leads to adipose inflammation and insulin resistance ([@bb0145], [@bb0190]). Consequently, empagliflozin may reduce the accumulation of T cells and M1 macrophages and increase the amount of M2 macrophages to alleviate inflammation and insulin resistance in obesity. The loss of glucose calories induced by empagliflozin is consistent with increased lipid mobilization, causing a reduction in fat mass and weight ([@bb0040], [@bb0035]). Thus, the anti-inflammatory effects of empagliflozin in the WAT and liver may be attributable to its impact on reducing both adiposity and hepatic steatosis.

In conclusion, the present study identified a potential mechanism by which SGLT2 inhibitors reduce obesity and control whole-body energy homeostasis. Empagliflozin-mediated SGLT2 inhibition enhances fat utilization and browning and attenuates obesity-induced inflammation and insulin resistance via M2 or alternative macrophage activation. Overall, the current investigation highlights the potential clinical utility of SGLT2 inhibition in the prevention of obesity and related metabolic disorders, such as insulin resistance, NAFLD, and type 2 diabetes.
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